

December 15, 2020

Securities and Exchange Commission
Department of Corporation Finance
Washington, D.C. 20549

Via: EDGAR Submission

Re: Checkpoint Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 27, 2020
File No. 333-251005

Ladies and Gentlemen:

Checkpoint Therapeutics, Inc. (the "Company"), hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 12:00 p.m. (ET) on December 17, 2020 or as soon as practicable thereafter, pursuant to Rule 461 of the Securities Act of 1933, as amended.

The Company acknowledges that (i) should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Please contact Mark F. McElreath of Alston & Bird LLP with any questions or comments at 212-210-9595. Thank you for your assistance with this filing.

CHECKPOINT THERAPEUTICS, INC.

By: /s/ James F. Oliviero
James F. Oliviero
Chief Executive Officer and President

cc: Mark F. McElreath, Esq.